January 21, 21 - 5:10 pm - LABS

Brazilian pharmaceutical defends Sputnik V emergency use approval before phase 3 trials

Representatives of the União Química laboratory had a meeting scheduled for the afternoon of Thursday (21) with the country’s health regulator Anvisa to defend the Sputnik V vaccine’s emergency use in Brazil before phase 3 in the country. The information is from the journalist Julia Dualibi‘s blog on G1.

The Russian vaccine against coronavirus, Sputnik V.
Photo: Courtesy/ Gamaleya Center, RDIF

The so-called phase 3 trials are mandatory for Anvisa to evaluate requests for emergency use of vaccines in Brazil. So far, only CoronaVac and the Oxford vaccine have achieved emergency clearance in the country. Two other laboratories carry out tests in Brazil, Pfizer, and Janssen.